Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF
  • Original article
  • Open access
  • Published:

Correlation of serum visfatin level with chest pain scoring as an indication of myocardial ischemia in chronic kidney disease patients

The Egyptian Journal of Internal Medicine volume 26, pages 45–52 (2014)Cite this article

Abstract

Background

Nicotinamide phosphoribosyltransferase (Visfatin), an enzyme involved in the NAD+ salvage pathway, has been shown to help in the regulation of glucose homeostasis. It is a highly conserved, 52 kDa protein found in living species from bacteria to humans. It is an adipokine produced and secreted primarily by adipose tissue. Chronic kidney disease (CKD) and end-stage renal disease patients showed increased cardiovascular mortality, and vascular events account for more than half of the deaths in this population. Myocardial ischemia is a consequence of coronary heart disease. Recent studies found that with increasing visfatin levels, CKD patients have a larger number of vessels with stenosis and a higher likelihood of coronary artery disease.

Research design and methods

The current prospective study includes 137 CKD patients and patients with chest pain (CP). as well as 20 patients as controls. Patient data included age, sex, comorbidities, smoking status, weight, height, and BMI, calculated using the equation: BMI = weight (kg)/height (m2). Estimated glomerular filtration rate was calculated using the modified Modification of Diet in Renal Disease equations; in addition, enzyme-linked immunosorbent assay was used to estimate serum visfatin levels, and CP was assessed through a modification of the master questionnaire.

Results

All patients had significantly (P < 0.05) higher serum visfatin levels compared with controls. Patients who had typical anginal CP had significantly (P < 0.05) higher serum visfatin levels compared with those who had atypical anginal or nonanginal CP, with nonsignificantly (P > 0.05) higher serum visfatin levels in patients with atypical anginal CP compared with those with nonanginal CP. Moreover, patients with stage 4 CKD had a significantly (P < 0.05) higher serum visfatin level compared with patients with stage 3 CKD.

Conclusion

It could be concluded that patients with CKD are at an actual risk of developing CP secondary to myocardial ischemic attack, presenting either as typical or as atypical anginal pain. Elevated serum visfatin levels may be the cornerstone for the relationship between CKD and coronary heart disease. Serum visfatin levels in range of 12.4–16.4 ng/ml could predict the possibility of developing an anginal attack in patients with atypical anginal CP, with high sensitivity and specificity for diagnosis.

References

  1. Matsui H, Tsutsumi A, Sugihara M, Suzuki T, Iwanami K, Kohno M, et al. Visfatin (pre-B cell colony-enhancing factor) gene expression in patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67: 571–572.

    Article  CAS  Google Scholar 

  2. Gandhi H, Upaganlawar A, Balaraman R. Adipocytokines: the pied pipers. J Pharmacol Pharmacother 2010; 1: 9–17.

    Article  CAS  Google Scholar 

  3. Zhang LQ, Heruth DP, Ye SQ. Nicotinamide phosphoribosyltransferase in human diseases. J Bioanal Biomed 2011; 3: 13–25.

    Article  Google Scholar 

  4. Sonoli SS, Shivprasad S, Prasad CV, Patil AB, Desai PB, Somannavar MS. Visfatin – a review. Eur Rev Med Pharmacol Sci 2011 ; 15: 9–14.

    CAS  PubMed  Google Scholar 

  5. Khan IA, Wattanasuwan N, Mehta NJ. Prognostic value of serum troponin I in ambulatory patients with chronic renal failure undergoing long-term hemodialysis: a two years outcome analysis. J Am Coll Cardiol 2000; 38: 991–998.

    Article  Google Scholar 

  6. Bejan-Angoulvant T, Bergerot C, Juillard L, Mezergues A, Morelon E, Pouteil-Noble C, et al. Myocardial microvascular disease and major adverse cardiovascular events in patients with end-stage renal disease: Rationale and design of the MICROCARD study. Nephrol Dial Transplant 2012;27: 2886–2891.

    Article  CAS  Google Scholar 

  7. Garrow J. Body composition for the investigation of obesity. Basic Life Sci 1990;55: 183–190.

    CAS  PubMed  Google Scholar 

  8. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461–470.

    CAS  Google Scholar 

  9. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K. Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426–430.

    Article  CAS  Google Scholar 

  10. Master AM. The spectrum of anginal and non cardiac pain. JAMA 1964; 187: 894–899.

    Article  CAS  Google Scholar 

  11. Murabito JM, Anderson KM, Kannel WB, Evans JC, Levy D. Risk of coronary heart disease in subjects with chest discomfort: the Framingham heart study. Am J Med 1990; 89: 297–302.

    Article  CAS  Google Scholar 

  12. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837–1847.

    Article  CAS  Google Scholar 

  13. Pryor DB, Harrell FEJr, Lee KL, Califf RM, Rosati RA. An improving prognosis over time in medically treated patients with coronary artery disease. Am J Cardiol 1983; 52: 444–448.

    Article  CAS  Google Scholar 

  14. Pryor DB, Shaw L, Harrell FEJr, Lee KL, Hlatky MA, Mark DB, et al. Estimating the likelihood of severe coronary artery disease. Am J Med 1991;90: 553–562.

    Article  CAS  Google Scholar 

  15. Nüsken KD, Petrasch M, Rauh M, Stöhr W, Nüsken E, Schneider H, Dötsch J. Active visfatin is elevated in serum of maintenance haemodialysis patients and correlates inversely with circulating HDL cholesterol. Nephrol Dial Transplant 2009; 24: 2832–2838.

    Article  Google Scholar 

  16. Bessa SS, Hamdy SM, El-Sheikh RG. Serum visfatin as a non-traditional biomarker of endothelial dysfunction in chronic kidney disease: an Egyptian study. Eur J Intern Med 2010; 21: 530–535.

    Article  CAS  Google Scholar 

  17. Lu YC, Hsu CC, Yu TH, Wang CP, Lu LF, Hung WC, et al. Association between visfatin levels and coronary artery disease in patients with chronic kidney disease. Iran J Kidney Dis 2013; 7: 446–452.

    PubMed  Google Scholar 

  18. Tang X, Chen M, Zhang W. Association between elevated visfatin and carotid atherosclerosis in patients with chronic kidney disease. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2013; 38: 553–559.

    CAS  PubMed  Google Scholar 

  19. Gunes F, Akbal E, Cakir E, Akyurek O, Altunbas M, Ozbek M. Visfatin may be a novel marker for identifying stages of essential hypertension in advanced age patients. Intern Med 2012; 51: 553–557.

    Article  CAS  Google Scholar 

  20. Karakan S, Sezer S, Özdemir Acar FN, Haberal M. The relationship of visfatin levels with insulin resistance and left ventricular hypertrophy in peritoneal dialysis patients. Ren Fail 2012; 34: 732–737.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Faculty of Medicine, Banha University, MD21462 gulil, Jeddah, P.O. Box 7500, Kingdom of Saudi Arabia

    Mohamed F. Almaghraby & Abeer A. Mahmoud

  2. Department of Cardiology, Beni Suef University, Egypt

    Mohamed F. Almaghraby & Abeer A. Mahmoud

Authors
  1. Mohamed F. Almaghraby
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abeer A. Mahmoud
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohamed F. Almaghraby.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Almaghraby, M.F., Mahmoud, A.A. Correlation of serum visfatin level with chest pain scoring as an indication of myocardial ischemia in chronic kidney disease patients. Egypt J Intern Med 26, 45–52 (2014). https://doi.org/10.4103/1110-7782.139520

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/1110-7782.139520

Keywords